Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 72,534 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 72,534 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $64.38, for a total value of $4,669,738.92. Following the completion of the sale, the director directly owned 1,564,407 shares of the company’s stock, valued at $100,716,522.66. The trade was a 4.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Liquidia Stock Up 1.9%

LQDA traded up $1.24 on Wednesday, reaching $65.25. The company’s stock had a trading volume of 2,327,936 shares, compared to its average volume of 1,722,392. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of 466.10 and a beta of 0.58. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $66.78. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The business’s 50 day moving average is $47.90 and its 200 day moving average is $40.11.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, research analysts forecast that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on LQDA shares. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Lifesci Capital upgraded Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. BTIG Research raised their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $55.63.

Institutional Trading of Liquidia

Hedge funds have recently modified their holdings of the business. Caprock Group LLC purchased a new stake in shares of Liquidia in the third quarter valued at $37,114,000. Apis Capital Advisors LLC bought a new position in Liquidia during the third quarter valued at about $9,569,000. Farallon Capital Management LLC raised its holdings in Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in shares of Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after buying an additional 24,555 shares during the period. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Liquidia in the third quarter valued at about $1,536,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).